erlotinib + ramucirumab

The combination of erlotinib and ramucirumab is a targeted therapy approach used primarily for the treatment of metastatic non-small cell lung cancer (NSCLC) with EGFR mutations. This combination was approved by the FDA in 2020 for first-line treatment of metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations[1]. ## Mechanism and Clinical Profile Erlotinib is a first-generation EGFR tyrosine kinase inhibitor (EGFR-TKI) that targets the epidermal growth factor receptor. Ramucirumab is a human monoclonal IgG1 antibody that selectively targets VEGF receptor 2 and blocks signaling mediated by VEGF-A, VEGF-C, and VEGF-D, giving it a broader range of anti-tumor activity than other VEGF inhibitors[4]. The combination was studied in the RELAY trial (NCT02411448), a global double-blind, placebo-controlled phase 3 study that demonstrated a statistically significant improvement in progression-free survival for patients receiving ramucirumab plus erlotinib compared to erlotinib alone[2]. Specifically: - Patients taking ramucirumab plus erlotinib lived an average of 19.4 months without disease progression compared to 12.4 months for those taking placebo plus erlotinib[2][3] - The hazard ratio for progression-free survival was 0.59 (95% CI: 0.46-0.76, p < 0.0001)[2] - Tumor shrinkage was observed in 76% of people taking ramucirumab plus erlotinib compared with 75% of those taking placebo plus erlotinib[3] However, the final overall survival analysis from the RELAY trial showed no significant improvement in overall survival between the two treatment arms, with a median OS of 51.1 months for ramucirumab plus erlotinib versus 46.0 months for placebo plus erlotinib (HR = 0.98, 95% CI: 0.78-1.24, p = 0.864)[2]. ## Dosing Information The recommended dosage for this combination is: - Ramucirumab: 10 mg/kg administered intravenously every 2 weeks - Erlotinib: 150 mg orally daily[1][3] ## Safety Profile The most common side effects of the combination include: - Infections - Increased levels of liver enzymes - Diarrhea - High blood pressure - Low red blood cell count - Mouth sores or inflammation - Low blood platelet count - Hair loss - Nosebleeds - Proteinuria (too much protein in the urine) - Decreased white blood cell counts - Low potassium levels - Peripheral edema (swelling in arms, legs, hands, and feet) - Headache - Gastrointestinal bleeding - Gum bleeding - Bleeding in the lungs or respiratory tract[3] The safety profile remained consistent over time with no new safety signals observed during long-term follow-up[2]. If infusion reactions occur, the ramucirumab infusion rate may be slowed or treatment may be permanently discontinued depending on the severity of the reaction[3]. ## Patient Selection The combination is specifically indicated for patients with: - EGFR exon 19 deletions or exon 21 L858R mutations - No central nervous system metastases at baseline[2] Interestingly, subgroup analyses suggest potential benefits in patients with poor prognosis factors such as L858R mutations or TP53 co-mutations, though these findings were not statistically significant[2].

Brand names

Cyramza + erlotinib

Other names

RAM + ERL